Dogwood Therapeutics Financials
This page shows Dogwood Therapeutics (DWTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Dogwood Therapeutics passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Dogwood Therapeutics generates $0.71 in operating cash flow (-$8.8M OCF vs -$12.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Dogwood Therapeutics's EBITDA was -$12.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
Dogwood Therapeutics reported -$12.3M in net income in fiscal year 2024. This represents a decrease of 133.2% from the prior year.
Dogwood Therapeutics earned $-12.52 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 77.6% from the prior year.
Dogwood Therapeutics held $14.8M in cash against $0 in long-term debt as of fiscal year 2024.
Dogwood Therapeutics had 1M shares outstanding in fiscal year 2024. This represents an increase of 72.9% from the prior year.
Dogwood Therapeutics invested $3.5M in research and development in fiscal year 2024. This represents an increase of 104.3% from the prior year.
DWTX Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $14.5M+2613.4% | $535K | N/A | $374K | N/A | $1.6M | N/A | $3.0M |
| SG&A Expenses | $1.3M-27.1% | $1.8M | N/A | $900K | N/A | $970K | N/A | $1.2M |
| Operating Income | -$15.8M-587.0% | -$2.3M | N/A | -$1.3M | N/A | -$2.6M | N/A | -$4.1M |
| Interest Expense | N/A | $23K | N/A | $39K | N/A | $17K | N/A | $2K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$15.7M-590.3% | -$2.3M | N/A | -$1.2M | N/A | -$2.6M | N/A | -$4.1M |
| EPS (Diluted) | $-8.20-300.0% | $-2.05 | N/A | $-1.62 | N/A | $-0.28 | N/A | $-0.49 |
DWTX Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $92.0M-2.5% | $94.3M+2164.1% | $4.2M-20.6% | $5.2M-37.3% | $8.4M-22.9% | $10.9M-31.2% | $15.8M-21.5% | $20.1M |
| Current Assets | $11.7M-29.6% | $16.5M+297.2% | $4.2M-20.6% | $5.2M-37.3% | $8.4M-22.9% | $10.9M-31.2% | $15.8M-21.5% | $20.1M |
| Cash & Equivalents | $10.1M-31.8% | $14.8M+347.6% | $3.3M-30.7% | $4.8M-31.9% | $7.0M-28.2% | $9.8M-30.1% | $14.0M-27.0% | $19.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $12.2M+3.4% | $11.8M | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $84.7M-18.9% | $104.4M+29026.5% | $359K-26.4% | $487K-53.3% | $1.0M-36.1% | $1.6M+28.0% | $1.3M+4.0% | $1.2M |
| Current Liabilities | $2.6M-18.2% | $3.2M+785.9% | $359K-26.4% | $487K-53.3% | $1.0M-36.1% | $1.6M+28.0% | $1.3M+4.0% | $1.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $7.3M+171.7% | -$10.1M-365.9% | $3.8M-20.1% | $4.8M-35.0% | $7.3M-20.6% | $9.2M-36.4% | $14.5M-23.2% | $18.9M |
| Retained Earnings | -$104.3M-41.3% | -$73.8M-20.1% | -$61.5M-1.8% | -$60.4M-7.5% | -$56.2M-3.8% | -$54.1M-23.2% | -$43.9M-11.4% | -$39.4M |
DWTX Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.3M+46.6% | -$6.1M-317.3% | -$1.5M-53.0% | -$960K+64.0% | -$2.7M-7.6% | -$2.5M+52.0% | -$5.2M-95.5% | -$2.6M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $0-100.0% | $15.3M | $0 | N/A | -$86K | N/A | $0 | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
DWTX Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -17.1%+82.8pp | -99.9% | N/A | -23.5% | N/A | -23.7% | N/A | -20.4% |
| Current Ratio | 4.49-0.7 | 5.21-6.4 | 11.62+0.8 | 10.77+2.8 | 8.02+1.4 | 6.65-5.7 | 12.37-4.0 | 16.39 |
| Debt-to-Equity | 11.67+22.0 | -10.31-10.4 | 0.090.0 | 0.10-0.0 | 0.14-0.0 | 0.18+0.1 | 0.09+0.0 | 0.07 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$10.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
Is Dogwood Therapeutics profitable?
No, Dogwood Therapeutics (DWTX) reported a net income of -$12.3M in fiscal year 2024.
What is Dogwood Therapeutics's earnings per share (EPS)?
Dogwood Therapeutics (DWTX) reported diluted earnings per share of $-12.52 for fiscal year 2024. This represents a -77.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Dogwood Therapeutics's EBITDA?
Dogwood Therapeutics (DWTX) had EBITDA of -$12.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Dogwood Therapeutics's operating cash flow?
Dogwood Therapeutics (DWTX) generated -$8.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Dogwood Therapeutics's total assets?
Dogwood Therapeutics (DWTX) had $94.3M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Dogwood Therapeutics spend on research and development?
Dogwood Therapeutics (DWTX) invested $3.5M in research and development during fiscal year 2024.
How many shares does Dogwood Therapeutics have outstanding?
Dogwood Therapeutics (DWTX) had 1M shares outstanding as of fiscal year 2024.
What is Dogwood Therapeutics's current ratio?
Dogwood Therapeutics (DWTX) had a current ratio of 5.21 as of fiscal year 2024, which is generally considered healthy.
What is Dogwood Therapeutics's debt-to-equity ratio?
Dogwood Therapeutics (DWTX) had a debt-to-equity ratio of -10.31 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Dogwood Therapeutics's return on assets (ROA)?
Dogwood Therapeutics (DWTX) had a return on assets of -13.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Dogwood Therapeutics's cash runway?
Based on fiscal year 2024 data, Dogwood Therapeutics (DWTX) had $14.8M in cash against an annual operating cash burn of $8.8M. This gives an estimated cash runway of approximately 20 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Dogwood Therapeutics's debt-to-equity ratio negative or unusual?
Dogwood Therapeutics (DWTX) has negative shareholder equity of -$10.1M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Dogwood Therapeutics's Piotroski F-Score?
Dogwood Therapeutics (DWTX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Dogwood Therapeutics's earnings high quality?
Dogwood Therapeutics (DWTX) has an earnings quality ratio of 0.71x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.